Research Progress of Botulinum Toxin Type A in the Treatment of Postherpetic Neuralgia

VernacularTitle:A型肉毒毒素治疗带状疱疹后神经痛的研究进展
Author: Fubo LI ¹ ; Gege GONG ; Yue ZHANG ; Cehua OU
Author Information

1. 西南医科大学附属医院疼痛科,四川泸州 646000
Publication Type:Journal Article
Keywords: Botulinum toxin type A; Postherpetic neuralgia; Neuropathic pain; Herpes zoster neuralgia
From: Herald of Medicine 2025;44(8):1297-1302
CountryChina
Language:Chinese
Abstract: Herpes zoster neuralgia(HZN)is a refractory neuropathic pain.Its incidence increases with age,along with higher prevalence of postherpetic neuralgia(PHN).The pain is severe and often lasts for months or even years,significantly impacting patients'work and life.How to reduce the pain level and prevent postherpetic neuralgia is the key to its treatment.However,conventional drug treatment often has adverse effects such as dizziness and drowsiness with low overall efficacy,which is not conducive to controlling and mitigating the pain.Botulinum toxin type A(BTX-A)is an exotoxin released by clostridium botulinum,which is simple to inject,and can effectively alleviate the pain level of PHN through mechanisms such as acting on synapses of neuromuscular junctions and inhibiting neuroinflammatory responses,thereby reducing the incidence of posterior neuralgia.This paper reviews the progress of BTX-A application in the diagnosis and treatment of PHN.